Table 3

S100 proteins predict response to RTX treatment

Shows improvement at 6 months
Crude
OR CI
P valueAdjusted
OR CI
P valueDisease activity
OR CI
P value
Serum S100A8/A9 0.80.5–1.30.40.70.4–1.30.30.30.07–0.9 0.038
Serum S100A12 10.8–1.40.810.7–1.40.90.30.07–0.9 0.036
Urine S100A8/A910.8–1.40.60.90.7–1.40.9
Urine S100A1210.9–1.30.310.8–1.20.8
Shows improvement at 12 months
Serum S100A8/A90.70.4–1.20.20.80.4–1.70.5
Serum S100A1210.7–1.40.910.7–1.50.9
Urine S100A8/A910.7–1.30.810.7–1.40.8
Urine S100A1210.8–1.20.80.90.7–1.30.8
Major clinical response at 6 months
Serum S100A8/A9 0.80.4–1.50.50.70.3–1.90.60.20.2–0.9 0.036
Serum S100A12 10.7–1.60.80.850.5–1.50.60.10.02–0.8 0.03
Urine S100A8/A90.990.7–1.40.91.10.7–20.6
Urine S100A1210.8–1.30.81.40.9–20.1
Major clinical response at 12 months
Serum S100A8/A90.80.4–1.50.50.80.4–1.90.6
Serum S100A120.90.6–1.30.70.90.6–1.40.6
Urine S100A8/A90.990.7–1.410.90.6–1.40.7
Urine S100A1210.8–1.20.90.90.7–1.30.8
  • Displayed are crude and adjusted ORs for S100 proteins alone and in combination with the outcome of being a responder to RTX. ORs, CIs and p values are displayed. The ‘disease activity’ column displays OR, CI and p value for this variable when S100 proteins and other variables are included as part of the model.

  • Adjusted for age, disease duration, renal disease (outcome ARI), disease activity (outcome higher disease), low C3 or C4 (outcome positive), anti-dsDNA (outcome positive) and steroid dose. Bold=significant for S100 protein.

  • Anti-dsDNA, anti-double-stranded DNA; ARI, acute renal infarction; RTX, rituximab.